Interesting read, I’m left unconvinced that traditional pharma is moving much slower than optimal. That would seem to imply that they’re leaving a lot of money on the table (quicker approval = longer selling the drug before patent expires).
I have three speculative ideas on why this might be. Cost of the process, ability to scale the process, and risk (e.g. amount of resources wasted if a drug fails at some stage in development).
As the article points out, pharma can do this when the incentives are right (COVID vaccines) which implies there’s a reason to not do it normally.
Interesting read, I’m left unconvinced that traditional pharma is moving much slower than optimal. That would seem to imply that they’re leaving a lot of money on the table (quicker approval = longer selling the drug before patent expires).
I have three speculative ideas on why this might be. Cost of the process, ability to scale the process, and risk (e.g. amount of resources wasted if a drug fails at some stage in development).
As the article points out, pharma can do this when the incentives are right (COVID vaccines) which implies there’s a reason to not do it normally.